Avacopan (Tavneos®). HTA ID: 22009

Assessment Status NCPE assessment ongoing
HTA ID 22009
Drug Avacopan
Brand Tavneos®
Indication In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic  polyangiitis.  
Assessment Process
Rapid review commissioned 14/02/2022
Rapid review completed 08/03/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avacopan (Tavneos®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/04/2022
Pre-submission consultation with Applicant 21/06/2022
Full submission received from Applicant 19/10/2022